Sodium Tetrachloroaurate

The dosage of Sodium Tetrachloroaurate must be highly individualized, particularly when used as an allergenic extract or an adrenergic agent.

• For Diagnostic Patch Testing: A small amount of 0.5% to 1.0% Sodium Tetrachloroaurate in petrolatum is applied to the skin (usually the back) using an occlusive patch. The patch is typically left in place for 48 hours, with readings taken at 48, 72, and 96 hours.
• For Allergen Immunotherapy: Treatment begins with a 'build-up phase.' The initial dose may be as low as 0.01 mcg, increasing weekly by 50-100% until a maintenance dose (typically 100-500 mcg) is reached. This phase usually lasts 3 to 6 months.
• For Adrenergic Support: In acute settings, doses are titrated based on clinical response (e.g., blood pressure or heart rate targets). Standard ranges for subcutaneous administration in adults may involve 0.1 mg to 0.5 mg per dose.

Sodium Tetrachloroaurate is not universally approved for pediatric use. When used in children (typically aged 6 and older for allergy testing):

• Dosage: Must be calculated based on body surface area (BSA) or weight. Pediatric doses are generally 50% of the adult starting dose, with much slower titration schedules to monitor for systemic gold toxicity or hypersensitivity.
• Safety: Children must be monitored for at least 60 minutes following any injection due to the higher risk of rapid-onset anaphylaxis in the pediatric population.

Renal Impairment

Because gold is primarily excreted by the kidneys, patients with a Creatinine Clearance (CrCl) below 60 mL/min require a dose reduction of 25-50%. It is contraindicated in patients with severe renal failure or nephrotic syndrome.

Hepatic Impairment

No specific dose adjustments are typically required for hepatic impairment, as the drug does not undergo significant hepatic metabolism. However, patients with jaundice or hepatic cirrhosis should be monitored for secondary coagulopathies.

Elderly Patients

Geriatric patients should start at the lowest possible dose. This population is more sensitive to the adrenergic effects of the drug, which can precipitate cardiac arrhythmias or hypertensive crises.

Sodium Tetrachloroaurate is almost exclusively administered by a healthcare professional in a clinical setting.

• Administration: Subcutaneous injections should be given in the outer aspect of the upper arm. The site should be rotated with each injection.
• Food/Drink: There are no specific food restrictions, but patients should be well-hydrated before administration to support renal clearance.
• Storage: Vials should be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). Do not freeze. Protect from light.

If a dose in an immunotherapy schedule is missed:

• Less than 1 week late: Administer the usual dose.
• 1-2 weeks late: The dose may need to be reduced by 50%.
• More than 3 weeks late: The build-up phase may need to be restarted from the beginning.

Consult your allergist immediately if a dose is missed.

Signs of Sodium Tetrachloroaurate overdose include:

• Acute Gold Toxicity: Severe abdominal pain, vomiting, bloody diarrhea, and a metallic taste in the mouth.
• Adrenergic Crisis: Severe hypertension, palpitations, chest pain, and pulmonary edema.
• Emergency Measures: Immediate administration of a chelating agent (such as dimercaprol) may be required to remove gold from the system. Supportive care for cardiovascular stability is paramount.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to self-administer this medication unless specifically trained and authorized by your physician.

Patients receiving Sodium Tetrachloroaurate frequently experience localized reactions, particularly when used for diagnostic or immunotherapeutic purposes. These include:

• Injection Site Reactions: Redness (erythema), swelling (edema), and itching (pruritus) at the site of injection. These typically resolve within 24 to 48 hours.
• Dermatitis: A localized rash or 'flare' reaction, especially in patients with pre-existing gold sensitivity.
• Metallic Taste: A transient sensation of metal in the mouth, often occurring shortly after injection.
• Adrenergic Symptoms: Mild increases in heart rate, jitteriness, or a 'racing heart' sensation due to the drug's alpha and beta-agonist properties.

• Chrysiasis: A permanent blue-gray discoloration of the skin or eyes caused by the deposition of gold particles, usually seen after cumulative dosing.
• Gastrointestinal Distress: Nausea, mild cramping, or loose stools.
• Headache: Often described as a 'throbbing' sensation, likely related to the drug's effect on vascular tone.
• Proteinuria: The presence of excess protein in the urine, which may indicate early-stage kidney irritation.

• Aplastic Anemia: A serious condition where the body stops producing enough new blood cells. This is a known risk of systemic gold therapy.
• Thrombocytopenia: A sudden drop in platelet counts, leading to easy bruising or bleeding.
• Corneal Gold Deposits: Fine gold particles depositing in the cornea (chrysiasis of the eye), which usually does not affect vision but requires monitoring.
• Peripheral Neuropathy: Numbness or tingling in the hands and feet.

> Warning: Stop taking Sodium Tetrachloroaurate and call your doctor immediately or seek emergency care if you experience any of the following:

• Anaphylaxis: Signs include difficulty breathing, swelling of the face or throat, rapid pulse, and a sharp drop in blood pressure.
• Nephrotic Syndrome: Characterized by severe swelling in the legs and ankles, foamy urine, and significant weight gain from fluid retention.
• Exfoliative Dermatitis: Severe skin peeling, redness, and inflammation covering large areas of the body.
• Cardiac Arrhythmias: Feeling like your heart is skipping beats, fluttering, or beating too hard and fast, which may lead to fainting.
• Severe Neutropenia: Signs of infection such as fever, chills, and sore throat that do not go away.

Prolonged use of Sodium Tetrachloroaurate can lead to cumulative gold toxicity. The most significant long-term risk is nephrotoxicity (kidney damage), which can progress to permanent renal failure if not detected early. Additionally, long-term adrenergic stimulation can lead to left ventricular hypertrophy (thickening of the heart muscle) or chronic hypertension. Regular monitoring of blood counts and kidney function is mandatory for any patient on long-term therapy.

No FDA black box warnings currently exist for Sodium Tetrachloroaurate. However, it carries significant class warnings regarding the risk of severe anaphylaxis common to all standardized allergenic extracts. Healthcare providers must be prepared to treat systemic allergic reactions, including the use of epinephrine, whenever this drug is administered.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Early detection of side effects is critical to preventing long-term complications.

Sodium Tetrachloroaurate is a potent pharmacological agent that must only be used under the direct supervision of a specialist (e.g., an allergist, immunologist, or clinical pharmacologist). The primary risks involve systemic allergic reactions and cumulative heavy metal toxicity. Patients must be screened for pre-existing gold sensitivity and cardiovascular stability before the first dose is administered.

As of 2026, there are no FDA black box warnings for Sodium Tetrachloroaurate. However, it is subject to the general requirements for Allergenic Extracts, which mandate that the drug be administered in a facility equipped with emergency resuscitative equipment, including oxygen, intravenous fluids, and vasopressors.

Allergic Reactions / Anaphylaxis Risk

There is a constant risk of systemic anaphylaxis with every dose of Sodium Tetrachloroaurate. This risk is higher during the 'build-up' phase of immunotherapy or if the patient is currently experiencing an asthma flare. Patients should remain in the clinic for at least 30 to 60 minutes after each injection.

Nephrotoxicity

Gold salts are known to cause glomerular injury. Sodium Tetrachloroaurate can cause membranous glomerulonephritis. Patients with a history of kidney disease must be monitored with monthly urinalysis to check for proteinuria.

Hematologic Toxicity

Serious blood dyscrasias, including leukopenia (low white blood cells) and aplastic anemia, have been reported with gold compounds. Baseline and periodic Complete Blood Counts (CBC) are required.

Cardiovascular Risks

Due to its alpha and beta-adrenergic agonist properties, Sodium Tetrachloroaurate can cause significant increases in blood pressure and heart rate. It should be used with extreme caution in patients with coronary artery disease, uncontrolled hypertension, or a history of stroke.

To ensure safety, the following tests are typically required during treatment:

• Urinalysis: Every 1-4 weeks to monitor for protein or blood in the urine.
• Complete Blood Count (CBC): Every 2-4 weeks to monitor for changes in white blood cells or platelets.
• Physical Exam: Regular skin checks for rashes or signs of chrysiasis.
• Cardiac Monitoring: Blood pressure and heart rate checks before and after each administration.

Sodium Tetrachloroaurate may cause dizziness, tremors, or palpitations shortly after administration. Patients should avoid driving or operating heavy machinery for at least 2 hours following an injection or until they are certain they are not experiencing an adverse reaction.

Alcohol should be avoided on the day of treatment. Alcohol can cause vasodilation, which may increase the rate of absorption of the drug and potentially worsen an allergic or adrenergic reaction.

If Sodium Tetrachloroaurate is discontinued after long-term use, there is no specific 'withdrawal syndrome.' However, the therapeutic benefits for allergy desensitization may be lost. If the drug is stopped due to toxicity (e.g., kidney or blood issues), it should never be restarted.

> Important: Discuss all your medical conditions, especially heart or kidney problems, with your healthcare provider before starting Sodium Tetrachloroaurate.

• Non-Selective Beta-Blockers (e.g., Propranolol): These drugs can block the beta-adrenergic effects of Sodium Tetrachloroaurate while leaving the alpha-adrenergic effects unopposed. This can lead to severe hypertension and reflex bradycardia. Furthermore, beta-blockers make epinephrine less effective if needed to treat an anaphylactic reaction.
• Other Gold Salts (e.g., Auranofin): Concurrent use increases the risk of acute gold toxicity and severe renal damage.
• MAO Inhibitors (e.g., Phenelzine): Using Sodium Tetrachloroaurate with MAOIs can lead to a 'hypertensive crisis' due to the accumulation of catecholamines.

• Tricyclic Antidepressants (TCAs): TCAs can potentiate the adrenergic effects of Sodium Tetrachloroaurate, increasing the risk of cardiac arrhythmias.
• Immunosuppressants (e.g., Methotrexate, Cyclosporine): These may mask the early signs of gold toxicity or increase the risk of bone marrow suppression.
• Antidiabetic Agents: Adrenergic agonists can increase blood glucose levels, potentially requiring an adjustment in insulin or oral hypoglycemic dosages.

• Diuretics: May worsen the nephrotoxic potential of gold by concentrating the drug in the renal tubules through dehydration.
• Antihypertensives: The vasoconstrictive effects of Sodium Tetrachloroaurate may antagonize the effects of blood pressure medications, leading to poor blood pressure control.

• Caffeine: High intake of caffeine can synergize with the beta-agonist properties of the drug, leading to excessive tremors, anxiety, and tachycardia.
• High-Sodium Diets: May influence the renal excretion of gold ions, though the clinical significance is usually minor.

• St. John’s Wort: May alter the sensitivity of adrenergic receptors, leading to unpredictable responses.
• Ephedra / Ma Huang: These contain natural ephedrine and should be avoided as they significantly increase the risk of cardiovascular side effects when combined with an adrenergic agonist.
• Ginkgo Biloba: May increase the risk of bleeding if the patient develops gold-induced thrombocytopenia.

• Thyroid Function Tests: Gold salts can occasionally interfere with protein-bound iodine results.
• Urinary Protein Tests: Sodium Tetrachloroaurate can cause false-positive results in certain dipstick tests for proteinuria.

Mechanism of Interactions

Most interactions with Sodium Tetrachloroaurate occur via pharmacodynamic pathways (overlapping effects on the heart or immune system) rather than pharmacokinetic pathways (CYP enzymes). The gold component primarily interacts through cumulative organ toxicity, while the adrenergic component interacts through receptor competition or synergy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter allergy or cold medicines.

Sodium Tetrachloroaurate must NEVER be used in the following circumstances:

• Severe Renal Insufficiency: Because the kidneys are the primary route of gold elimination, impaired function leads to rapid, toxic accumulation.
• History of Gold-Induced Toxicity: If a patient has previously experienced exfoliative dermatitis, aplastic anemia, or nephrotic syndrome due to any gold compound, they must not receive Sodium Tetrachloroaurate.
• Uncontrolled Hypertension: The adrenergic agonist properties of the drug can trigger a stroke or myocardial infarction in these patients.
• Acute Asthma: Patients in the midst of an asthma exacerbation are at a significantly higher risk of fatal anaphylaxis when receiving allergenic extracts.

Healthcare providers will perform a careful risk-benefit analysis in patients with:

• Autoimmune Disorders (e.g., Lupus): Gold salts can sometimes exacerbate systemic lupus erythematosus.
• Pregnancy: Use only if the potential benefit outweighs the risk to the fetus.
• Active Infection: Systemic infections can alter the immune response to allergenic extracts.
• Compromised Cardiac Reserve: Patients who cannot tolerate a sudden increase in heart rate or blood pressure.

Patients who are allergic to other precious metals (such as platinum or palladium) may exhibit cross-sensitivity to Sodium Tetrachloroaurate. Furthermore, patients with known hypersensitivity to bee or wasp venom must be treated with extreme caution, as this drug is often used as a standardized extract for these very allergens.

> Important: Your healthcare provider will evaluate your complete medical history, including any past reactions to jewelry or dental work, before prescribing Sodium Tetrachloroaurate.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Sodium Tetrachloroaurate in pregnant women. Animal reproduction studies have shown that gold salts can be teratogenic (causing birth defects), particularly affecting the skeletal and renal systems.

• First Trimester: Use is generally avoided due to the risk of organogenesis interference.
• Late Pregnancy: The adrenergic effects could theoretically affect uterine blood flow. Use during pregnancy should be restricted to cases where the mother's life is at risk (e.g., severe venom allergy with no alternative).

Gold ions are excreted into human breast milk. While the amount absorbed by the infant is small, there is a theoretical risk of gold-induced rashes or kidney issues in the nursing child. Breastfeeding is generally not recommended while receiving regular doses of Sodium Tetrachloroaurate. If used, the infant should be monitored for skin changes and proper weight gain.

Sodium Tetrachloroaurate is not recommended for children under the age of 6. In older children, it is used primarily for diagnostic testing. Pediatric patients are at a higher risk for systemic reactions and must be monitored more closely than adults. Long-term effects on growth and development have not been established.

Patients over age 65 are more likely to have underlying cardiovascular and renal disease.

• Cardiac Risk: Increased risk of atrial fibrillation or hypertensive urgency from the adrenergic MoA.
• Renal Clearance: Natural decline in GFR (Glomerular Filtration Rate) means gold clears more slowly, increasing the risk of toxicity. Lower starting doses and frequent monitoring are essential.

• Mild (CrCl 60-90 mL/min): No adjustment usually needed, but monitor urine protein weekly.
• Moderate (CrCl 30-59 mL/min): Reduce dose by 50%.
• Severe (CrCl <30 mL/min): Contraindicated.
• Dialysis: Gold is not effectively removed by hemodialysis due to high protein binding.

While gold is not processed by the liver, patients with severe hepatic disease may have decreased albumin levels. Since gold binds to albumin, low levels can lead to higher concentrations of 'free' (unbound) gold, which is more toxic. Dose adjustments should be based on serum albumin levels.

> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring.

Sodium Tetrachloroaurate functions through two distinct pathways:

1. 1Immunological Modulation: As a standardized allergenic extract, it introduces gold-chloride complexes to antigen-presenting cells (APCs). This process promotes the desensitization of IgE-sensitized mast cells and basophils. Over time, it induces 'T-cell tolerance' and increases the ratio of IgG4 to IgE antibodies.
2. 2Adrenergic Agonism: The molecule acts as a direct agonist at Alpha-1, Alpha-2, Beta-1, and Beta-2 adrenergic receptors. This stimulates the sympathetic nervous system, leading to vasoconstriction (alpha-mediated) and bronchodilation (beta-mediated).

• Onset of Action: Adrenergic effects (increased heart rate/BP) occur within 5-15 minutes of injection. Immunological changes (desensitization) take months to develop.
• Duration: The adrenergic effect lasts 1-4 hours. The immunological effect can last for years after a full course of therapy.
• Dose-Response: There is a narrow therapeutic window; small increases in dose can lead to significant jumps in systemic gold levels.

| Parameter | Value |

|---|---|

| Bioavailability | 90-100% (Subcutaneous) |

| Protein Binding | 95% (Primarily Albumin) |

| Half-life | 7 to 30 days (Terminal) |

| Tmax | 2 to 6 hours |

| Metabolism | Non-enzymatic dissociation |

| Excretion | Renal 70%, Fecal 30% |

• Molecular Formula: NaAuCl₄
• Molecular Weight: 361.77 g/mol
• Solubility: Highly soluble in water; soluble in ethanol.
• Structure: Consists of a sodium cation and a square planar tetrachloroaurate(III) anion. It is a bright orange-yellow crystalline solid in its pure form.

Sodium Tetrachloroaurate is classified as a Standardized Allergenic Extract and a Sympathomimetic Amine. It is related to other gold salts like Sodium Aurothiomalate, but is distinct due to its chloride ligands and specific adrenergic MoA profile.